Q4'25 & FY25 Financial Results Webcast & Call March 23, 2026 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for ...

Financial Performance - Revenue reached $7.4 million, a 21% increase compared to Q3 2024[13] - Core revenue increased by 12% compared to Q3 2024[13] - Non-GAAP gross margin improved to 46%, significantly higher than the 26% in Q3 2024[13] - Non-GAAP operating expenses decreased by 40% compared to Q3 2024, totaling $9.7 million[13] Operational Highlights - Flowcells sold increased by 7% to 8,390 compared to Q3 2024[13] - The OGM installed base grew by 4% compared to Q3 2024, reaching 384 systems[13] - Seven new OGM installations were completed in Q3 2025, bringing the year-to-date total to 23[13] Strategic Focus and Outlook - The company completed a $10 million public offering of common stock in September 2025[13] - Cash, cash equivalents, and available-for-sale securities totaled $31.8 million as of September 30, 2025[13] - The company is reiterating its full-year 2025 revenue guidance of $26 - $30 million[30] - The company expects new OGM installations to surpass 25 systems for FY 2025, exceeding prior expectations of 20-25 systems[30]